Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2

2:

• The method of claim 1, wherein the HbA1c is reduced by about 0.73%.

3:

• The method of claim 1, wherein the HbA1c is reduced by about 0.61% to about 0.84%.

4:

• The method of claim 1, wherein the HbA1c is reduced by about 0.85%.

5:

• The method of claim 1, wherein the HbA1c is reduced by about 0.73% to about 0.969%.

6:

• The method of claim 1, wherein the HbA1c is reduced by at least about 0.6%.

7:

• A method of improving glycemic control in a patient with untreated type 2 diabetes mellitus comprising:
• administering once daily to the patient a therapeutically effective amount of desPro36Exendin-4(1-39)-Lys6-NH2 (“lixisenatide”) and/or a pharmaceutically acceptable salt thereof;
• wherein the improvement of glycemic control in the patient leads to a significant reduction of glucose excursion (mmol/L).

8:

• The method of claim 7, wherein the glucose excursion is reduced by about 3.77 mmol/L.

9:

• The method of claim 7, wherein the glucose excursion is reduced by about 3.316 mmol/L to about 4.224 mmol/L.

10:

• The method of claim 7, wherein the glucose excursion is reduced by about 4.36 mmol/L.

11:

• The method of claim 7, wherein the glucose excursion is reduced by about 3.924 mmol/L to about 4.796 mmol/L.

12:

• The method of claim 7, wherein the glucose excursion is reduced by at least about 3.3 mmol/L.

13:

• The method of claim 7, wherein the glucose excursion is reduced by about 75%.